Literature DB >> 9790524

Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice.

Z Hanna1, D G Kay, N Rebai, A Guimond, S Jothy, P Jolicoeur.   

Abstract

Transgenic (Tg) mice expressing the complete coding sequences of HIV-1 in CD4+ T cells and in cells of the macrophage/dendritic lineages develop severe AIDS-like pathologies: failure to thrive/weight loss, diarrhea, wasting, premature death, thymus atrophy, loss of CD4+ T cells, interstitial pneumonitis, and tubulo-interstitial nephritis. The generation of Tg mice expressing selected HIV-1 gene(s) revealed that nef harbors a major disease determinant. The latency and progression (fast/slow) of the disease were strongly correlated with the levels of Tg expression. Nef-expressing Tg thymocytes were activated and alpha-CD3 hyperresponsive with respect to tyrosine phosphorylation of several substrates, including LAT and MAPK. The similarity of this mouse model to human AIDS, particularly pediatric AIDS, suggests that Nef may play a critical role in human AIDS, independently of its role in virus replication.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9790524     DOI: 10.1016/s0092-8674(00)81748-1

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  179 in total

1.  Mechanism for down-regulation of CD28 by Nef.

Authors:  T Swigut; N Shohdy; J Skowronski
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

2.  Nef-induced major histocompatibility complex class I down-regulation is functionally dissociated from its virion incorporation, enhancement of viral infectivity, and CD4 down-regulation.

Authors:  H Akari; S Arold; T Fukumori; T Okazaki; K Strebel; A Adachi
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  The Nef protein of HIV-1 associates with rafts and primes T cells for activation.

Authors:  J K Wang; E Kiyokawa; E Verdin; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions.

Authors:  E Schaeffer; R Geleziunas; W C Greene
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

5.  Advances in our understanding of the pathogenesis of HIV-1 associated nephropathy in children.

Authors:  Patricio E Ray; Chien-An A Hu
Journal:  Future Virol       Date:  2011-07       Impact factor: 1.831

6.  Disrupting surfaces of nef required for downregulation of CD4 and for enhancement of virion infectivity attenuates simian immunodeficiency virus replication in vivo.

Authors:  A J Iafrate; S Carl; S Bronson; C Stahl-Hennig; T Swigut; J Skowronski; F Kirchhoff
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4(+) T cells.

Authors:  C Cicala; J Arthos; A Rubbert; S Selig; K Wildt; O J Cohen; A S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-01       Impact factor: 11.205

8.  Development and validation of a high-content bimolecular fluorescence complementation assay for small-molecule inhibitors of HIV-1 Nef dimerization.

Authors:  Jerrod A Poe; Laura Vollmer; Andreas Vogt; Thomas E Smithgall
Journal:  J Biomol Screen       Date:  2013-11-26

Review 9.  Immunopathogenesis of oropharyngeal candidiasis in human immunodeficiency virus infection.

Authors:  Louis de Repentigny; Daniel Lewandowski; Paul Jolicoeur
Journal:  Clin Microbiol Rev       Date:  2004-10       Impact factor: 26.132

10.  Down-modulation of mature major histocompatibility complex class II and up-regulation of invariant chain cell surface expression are well-conserved functions of human and simian immunodeficiency virus nef alleles.

Authors:  Michael Schindler; Stephanie Würfl; Philippe Benaroch; Thomas C Greenough; Rod Daniels; Philippa Easterbrook; Matthias Brenner; Jan Münch; Frank Kirchhoff
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.